Amifostine

Amifostine (WR2721) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer. Amifostine protects cells from damage by scavenging oxygen-derived free radicals. Amifostine reduces renal toxicity and has antiangiogenic action[1][2][3][4].

Product Specifications

CAS Number

[20537-88-6]

Product Name Alternative

WR2721

UNSPSC

12352211

Hazard Statement

H302

Target

HIF/HIF Prolyl-Hydroxylase; MDM-2/p53

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Amifostine.html

Purity

99.95

Solubility

DMSO : < 1 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

OP(SCCNCCCN)(O)=O

Molecular Formula

C5H15N2O3PS

Molecular Weight

214.22

Precautions

H302

References & Citations

[1]Kouvaris, J.R., V.E. Kouloulias, and L.J. Vlahos, Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist, 2007. 12 (6) : p. 738-47.|[2]D Maurici, et al. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene. 2001 Jun 14;20 (27) :3533-40.|[3]Efstathia Giannopoulou, et al. Amifostine inhibits angiogenesis in vivo. J Pharmacol Exp Ther. 2003 Feb;304 (2) :729-37.|[4]Michael I Koukourakis, et al. Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1 alpha. Cancer Chemother Pharmacol. 2004 Jan;53 (1) :8-14.|[5]Shao-Ze Wu, et al. Amifostine Pretreatment Attenuates Myocardial Ischemia/Reperfusion Injury by Inhibiting Apoptosis and Oxidative Stress. Oxid Med Cell Longev. 2017;2017:4130824.